RE:RE:CXRX Bought Drugs To Jack up PricesThe thing is Valeant has a moat on many products so they have a certain amount of pricing power. Cxr on the other hand is more subject to market pressure from competitors. You don't have to look any further than Plaquenil where they took a big writedown, lowered prices and in the last Rbc report they said there has been further pricing pressure again.
cg16 wrote: I think its unlikely that price increases will stop.
This is from last week:
"In a statement, Valeant Pharmaceuticals (VRX -2.2%) says it has raised the wholesale acquisition prices of its neurology, gastrointestinal and urology products by 2 - 9% effective today."